UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $90.13 and traded as high as $94.39. UCB shares last traded at $94.27, with a volume of 8,082 shares.
UCB Stock Down 1.6 %
The company has a 50 day moving average price of $90.13 and a 200-day moving average price of $78.01.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- How to Invest in Small Cap Stocks
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Trading Halts Explained
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
